AUG 22, 2020 9:21 AM PDT

Could a Drug for Bipolar Disorder Treat COVID-19?

WRITTEN BY: Annie Lennon

Researchers have found that a drug currently used to treat bipolar disorder and hearing loss may also treat COVID-19 thanks to itsantibacterial and anti-inflammatory properties. 

Known as Ebselen, the new findings come after previous research showing it is able to block enzymes known as ‘Mpro’ that are necessary for the coronavirus to replicate in healthy cells. 

For the most recent study, researchers from the University of Chicago created computer models to understand how the drug and Mpro interact. In the end, they found that Ebelsen is able to bind to two different sites on the enzyme- both key for its function and ability to replicate. 

These findings suggest that Ebelsen may be a good drug candidate to treat COVID-19- especially as it is already in use, demonstrating its safety. The researchers also say that the drug highlights another vulnerability of the coronavirus that scientists may want to continue to investigate as the search for other drug candidates persist. 

Although promising results, however, the researchers also say that a lot more research is needed before they can properly determine how effective the drug may be at treating COVID-19. While computer models show it may be effective, real-life trials outside of the lab are needed to confirm its effectiveness. 

As such, while research may advance on this drug candidate, the researchers plan to focus their research on finding ore of SARS-CoV-2’s weak spots. 

“The main protease is one of many proteins in the virus that could be targeted with existing, repurposed drugs, and there are thousands of compounds to be considered,” says Professor Juan de Pablo, one of the study’s authors. 

“We are systematically investigating each of the proteins involved in the virus function and investigating their vulnerabilities and their responses to a wide range of drugs.”

 

Sources: Science AdvancesMedical News Today

About the Author
University College London
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
APR 22, 2022
Health & Medicine
Differences in the Impact of Acute and Chronic Cannabis Use on Stress Response Regulation
APR 22, 2022
Differences in the Impact of Acute and Chronic Cannabis Use on Stress Response Regulation
A new study published in Frontiers examined the influence of acute and chronic cannabis use on stress regulation. Althou ...
APR 28, 2022
Health & Medicine
Antidepressants Not Associated Improved Quality of Life
APR 28, 2022
Antidepressants Not Associated Improved Quality of Life
According to a recently published study in PLoS, antidepressants do not improve health-related quality of life (HRQoL) o ...
MAY 15, 2022
Drug Discovery & Development
Implanted Insulin-producing Cells for Diabetes Treatment
MAY 15, 2022
Implanted Insulin-producing Cells for Diabetes Treatment
Type 1 diabetes, which affects about 9 to 10 million people globally, occurs when the immune system incorrectly identifi ...
JUN 19, 2022
Drug Discovery & Development
Oral Immunotherapy for Peanut Allergy Most Effective Before 12 Months Old
JUN 19, 2022
Oral Immunotherapy for Peanut Allergy Most Effective Before 12 Months Old
Oral immunotherapy for peanut allergies is safer and more effective in children under 12 months old than in toddlers and ...
JUN 27, 2022
Plants & Animals
Developing a New Approach to Rabies Vaccination
JUN 27, 2022
Developing a New Approach to Rabies Vaccination
Rabies is a viral disease that can spread through the saliva. Several kinds of animals can get rabies, including humans ...
JUN 27, 2022
Drug Discovery & Development
Potential Gene Targets Identified for Treating Deafness
JUN 27, 2022
Potential Gene Targets Identified for Treating Deafness
Researchers have identified three mutations of the MINAR2 gene that are linked to deafness. They say that the mutations ...
Loading Comments...